A nationwide, multi-centric study conducted across 25 tertiary hospitals in India has found no evidence linking COVID-19 vaccinations Covishield or Covaxin to an increased risk of thrombotic events, including heart attacks, among adults aged 18 to 45.The findings provide reassurance to the public amid lingering concerns about vaccine safety in relation to cardiovascular health.The report, prepared by the Indian Council of Medical Research (ICMR), also involves medical instructions by Christian Medical College, Ludhiana, and Post Graduate Institute of Medical Education and Research (PGIMER).A report released today by the National Institute of Epidemiology (ICMR) reads, “Myocardial infarction (acute coronary artery thrombotic event) in young adults is known to be associated with certain comorbidities and lifestyle factors. The causal relationship between COVID-19 vaccination and thrombotic events has been debated globally, with varying risks being reported across populations and vaccine platforms. Considering reports of myocardial infarction and other thrombotic events in apparently healthy individuals, this study was conducted to determine the association between COVID-19 vaccination, lifestyle, medical risk factors, and thrombotic events among young adults in India.”Researchers noted that thrombotic events in this age group were primarily driven by traditional medical and lifestyle factors. Smoking, pre-existing health conditions, family history of clotting disorders, and prior severe Covid-19 infection emerged as the dominant contributors. “The study emphasised that vaccination itself was not associated with heightened risk,” reads the report.Experts involved in the research highlighted the importance of shifting public health focus toward addressing modifiable cardiovascular risk factors.”We conducted a multi-centric matched case-control study across 25 tertiary hospitals in India between October 2021 and January 2023. Cases were 18 to 45-year-old hospitalised patients with new arterial or venous thrombotic events. Hospitalised cases and controls were matched by admission date (±7 days). Data on exposure factors were obtained through hospital records and telephonic interviews. Conditional logistic regression was used to estimate matched odds ratios (mOR) with confounder adjustments guided by a directed acyclic graph,” stated the report.🚨 New Research Update 🚨Our nationwide, multi-centric study, conducted across 25 tertiary hospitals, found no link between COVID-19 vaccination (Covishield and Covaxin) and an increased risk of thrombotic events, including heart attacks, among young adults (18-45) in India.… pic.twitter.com/BlVLlq0bOP— ICMR National Institute of Epidemiology (@icmr_nie) July 13, 2026The report further reads, “We analysed 432 cases (1,293 controls) of acute myocardial infarction and 767 cases (2,144 controls) of any thrombotic event. Acute myocardial infarction was associated with previous history of any thrombotic event matched odds ratio (mOR) 60.0; 95%confidence interval (CI): 11.4, 315.1], comorbidities [adjusted mOR (amOR) 4.6; 95% CI: 2.0-10.5], ever smoking (amOR 3.5; 95% CI: 2.3-5.3) and family history of thrombotic event (mOR 3.3; 95% CI: 1.7-6.5).Receiving two or more doses of any Covid-19 vaccine (amOR 0.8; 95% CI: 0.3-2.8) was not associated with acute myocardial infarction. Analyses showed an association of any thrombotic event with prior history of thrombotic event, comorbidities, ever smoking, prior Covid-19 hospitalisation and family history of thrombotic event. There was no association between any thrombotic event and two or more doses (amOR 1.0; 95% CI: 0.5-2.0) of any COVID-19 vaccination. Similar associations were seen when analysed separately for CovishieldTM and CovaxinTM,” stated the report.Efforts should prioritise reducing smoking rates, managing chronic health conditions, and closely monitoring individuals who have recovered from severe Covid-19 infections, reads the statement issued today by ICMR.